- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 ; volume:18 ; number:1 ; day:6 ; month:11 ; year:2019 ; pages:1-14 ; date:12.2019
Molecular cancer ; 18, Heft 1 (6.11.2019), 1-14, 12.2019
- Urheber
-
Qin, Shuang
Xu, Linping
Yi, Ming
Yu, Shengnan
Wu, Kongming
Luo, Suxia
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-019-1091-2
- URN
-
urn:nbn:de:101:1-2020030317540630147430
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2024, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Qin, Shuang
- Xu, Linping
- Yi, Ming
- Yu, Shengnan
- Wu, Kongming
- Luo, Suxia
- SpringerLink (Online service)
Ähnliche Objekte (12)
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Moving Beyond the Asylum Muddle
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Moving Beyond the Asylum Muddle
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Moving Beyond the Asylum Muddle